Alexion Pharmaceuticals, Inc. company logo

# 1st Gen Model Alexion Pharmaceuticals, Inc. Pharmaceutical preparations

56.10% successful of 82 deals
$113.09 Last close price
at 14-dec-2017

ALXN

Model's trade recommendations -2.21% Return for period

-4.48% Annual return

$25.37B Market Cap

β 1.18  

ALXN

Model (following trade recommendations)

ALXN

Underlying stock

S&P 500

Index
Return for period -2.21%
2.50%
1.78%
52wk return -33.56%
-3.09%
16.82%
52wk Range
97.70—146.69
2000.54—2399.63
Sortino ratio -0.02
Sharpe ratio -0.01
Norm. RMSE 0.65%
Downside risk 16.36%
Volatility 32.24%
  • STRONG BUY Analysts consensus recommendation

Alexion Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and refractory generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). As the leader in complement biology for over 20 years, Alexion focuses its research efforts on novel molecules and targets in the complement cascade, and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Alexion Pharmaceuticals, Inc. (ALXN) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for ALXN model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 214M
P/E 23.22
Shares Outstanding 223M
% Held by Insiders 4.35%
% Held by Institutions 94.33%
EPS (last reported FY) $3.78
EPS (last reported Q) $1.28
EPS, estimated (last reported Q) $1.13
Total revenues $3 B
Net income $0 B